This workshop aims to provide a comprehensive overview of the exciting field of iCancer Immunotherapy from the latest biologic insights to the immuno-oncology pathways, key learnings in translating research findings to the clinic, latest clinical data on approved immuno-oncology agents and emerging agents in the pipelineas well as trends in business partnerships.

• Overview and Fundamentals of cancer immunotherapy
• Immunologic Strategies for Leukemia and Lymphoma (working title) (Holbrook Kohrt, MD, PhD, Assistant Professorof Medicine, Stanford Cancer Institute)
• Maximizing the benefit of anti-PD-1 therapy (Gary Starling PhD, Associate Vice President, Biologics Discovery Operations, Merck)
• Multipronged Approach with Immunotherapy and Direct Targeted Killing to Say Bye2Cancer (Sanjay Khare PhD, President & CEO, ImmuneGene)
• Finding Gold in the Goldilocks Zone, the Flexus Story of Drug Discovery in Immuno-Oncology (Juan Jaen, PhD, Former President & Head R&D, Flexus)
• Unlocking Immuno-Oncology Therapeutic Potential of PI3 Kinase and HDAC (Stephen Shuttleworth, PhD, FRSC, Chief Scientific Officer, KarusTherapeutics)
• Bioanalytical Strategies and Challenges for Large Molecule Cancer Immunotherapy Drug Development  (Eric Wakshull, PhD, Senior Scientist/ Group Leader, Genentech)
• Chasing Gold: Cancer Immunotherapy Deals & Business Outlook (Cheni Kwok PhD CLP, Managing Partner, Linear Dreams)